Tg Therapeutics (TGTX) Total Debt (2010 - 2026)

Tg Therapeutics' Total Debt history runs 15 years deep, the most recent figure standing at $745.1 million for Q1 2026.

• In Q1 2026, Total Debt rose 204.47% year-over-year to $745.1 million; the TTM figure through Mar 2026 stood at $745.1 million (up 204.47% YoY), while the FY2025 annual figure was $245.6 million, changed 0.5% from the prior year.
• Total Debt for Q1 2026 stood at $745.1 million, up from $245.6 million in the prior quarter.
• The five-year high for Total Debt was $745.1 million in Q1 2026, with the low at $67.2 million in Q1 2022.
• The 5-year median for Total Debt is $101.3 million (2024), against an average of $181.8 million.
• The sharpest annual moves came in 2022 and 2025: Total Debt surged 344.62% in 2022, then advanced 0.48% in 2025.
• Tg Therapeutics' Total Debt stood at $71.1 million in 2022, then soared by 40.74% to $100.1 million in 2023, then soared by 144.14% to $244.4 million in 2024, then increased by 0.5% to $245.6 million in 2025, then jumped by 203.34% to $745.1 million in 2026.
• Business Quant data shows TGTX's Total Debt at $745.1 million in Q1 2026, $245.6 million in Q4 2025, and $245.3 million in Q3 2025.